AI assistant
Cartesian Therapeutics, Inc. — Director's Dealing 2022
Apr 14, 2022
33483_dirs_2022-04-13_ff5a2727-c1f1-4ac6-8702-0f8284cb3f0a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: SELECTA BIOSCIENCES INC (SELB)
CIK: 0001453687
Period of Report: 2022-04-11
Reporting Person: SPRINGER TIMOTHY A (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-11 | Common Stock | P | 6681600 | — | Acquired | 29868490 | Indirect |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-11 | Warrant (right to buy) | $1.55 | A | 5011200 | Acquired | 2027-04-11 | Common Stock (5011200.0) | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 7293625 | Direct |
| Common Stock | 86418 | Indirect |
Footnotes
F1: Each share of common stock and accompanying warrant to purchase 0.75 shares of common stock was purchased at a combined ofering price of $1.41. The shares of common stock and accompanying warrants were acquired by the reporting person as units, but were issued separately and were immediately separable upon issuance.
F2: Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.